IN8bio (INAB) Expected to Announce Quarterly Earnings on Thursday

IN8bio (NASDAQ:INAB) is expected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

IN8bio Stock Up 0.6%

NASDAQ INAB opened at $1.73 on Thursday. IN8bio has a 52 week low of $1.17 and a 52 week high of $8.24. The business has a 50 day moving average price of $2.05 and a 200-day moving average price of $2.00. The company has a market cap of $16.90 million and a price-to-earnings ratio of -0.32.

Hedge Funds Weigh In On IN8bio

Several large investors have recently bought and sold shares of INAB. HRT Financial LP purchased a new position in IN8bio during the 4th quarter worth $34,000. Captrust Financial Advisors bought a new position in shares of IN8bio during the fourth quarter valued at about $43,000. Citadel Advisors LLC purchased a new position in IN8bio during the third quarter worth about $54,000. Two Sigma Investments LP purchased a new position in IN8bio during the third quarter worth about $107,000. Finally, Franklin Resources Inc. grew its position in IN8bio by 381.6% in the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after purchasing an additional 724,637 shares in the last quarter. 92.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Zacks Research raised shares of IN8bio to a “hold” rating in a research report on Thursday, January 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $92.00.

IN8bio Company Profile

IN8bio, Inc (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline.

IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications.